Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
Adam M. Petrich, Koen van Besien, Justin Kline, Krishna Rao, Sreenivasa Nattam, Ajay Major, Amy S. Kimball, Aaron P. Rapoport, Kenneth J. Cohen, Bethany G. Sleckman, Sonali M. Smith, Theodore Karrison, Paul A. S. Fishkin
Publikováno v:
Haematologica. 107(7)
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the
Autor:
A. Badros, Dianna S. Howard, Barry R. Meisenberg, Donna E. Reece, David H. Vesole, Joanne Filicko-O'Hara, Jasleen K Randhawa, Neal Flomenberg, Parameswaran Hari, Aaron P. Rapoport, Gordon L. Phillips
Publikováno v:
Bone Marrow Transplantation. 54:293-299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220–260 mg/m2, although relatively well tolerated, have not shown significant improvement
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Ajay Major, Justin Kline, Kenneth J. Cohen, Adam M. Petrich, Amy S. Kimball, Bethany G. Sleckman, Koen van Besien, Paul A. S. Fishkin, Aaron P. Rapoport, Theodore Karrison, Sreenivasa Nattam, Sonali M. Smith
Publikováno v:
Blood. 136:43-44
Background Targeting the PI3K/Akt/mTOR axis in relapsed lymphomas is of interest based on constitutive activation in many lymphoma subtypes, and has had varying degrees of success. We previously showed that the first generation mTOR inhibitor, temsir
Autor:
Ali Bukhari, Linda Ridge, Nancy M. Hardy, Kathleen Ruehle, Saurabh Dahiya, Jason K. Molitoris, Natalie Gahres, Santanu Samanta, Forat Lutfi, Aaron P. Rapoport, Hanan Alkhaldi, Justin N. Malinou, Olga Goloubeva, Nicolette Minas, Pranshu Mohindra, Gabriela Sanchez-Petitto, Jean Yared
Publikováno v:
Blood. 136:20-21
Background: Nonmyeloablative (NMA) and reduced-intensity conditioning (RIC) regimens are offered for patients with hematologic malignancies requiring allogeneic stem cell transplantation (HSCT) but are not candidates for myeloablative conditioning (M
Autor:
Lina Bisharat, David J. Chung, Kelly A. O’Brien, Peiman Hematti, Robert J. Soiffer, David Avigan, David H. McKenna, Lynne Uhl, Jiaxi Zhu, Michele Herman, Natalie S. Callander, Nancy L. Geller, Yvonne A. Efebera, James W. Young, Courtney Nelson, Jacalyn Rosenblatt, Thinle Chodon, Aaron P. Rapoport, Pallawi Torka, Marcelo C. Pasquini, Binod Dhakal, Hillard M. Lazarus, Nina Shah, Ajay K. Nooka, Juan Wu, Lynn O'Donnell, Edmund K. Waller, Dina Stroopinsky, Brent R. Logan
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S62-S63
BMT CTN 1401 is an academically led randomized study of a personalized cancer vaccine in which the combination of DC/MM fusion vaccine and lenalidomide maintenance after autoHCT is compared with maintenance alone as upfront treatment of MM (NCT#02728
Autor:
Alison R. Sehgal, David B. Miklos, Loretta J. Nastoupil, Abhinav Deol, Julie M. Vose, Javier Munoz, Patrick M. Reagan, N. Nora Bennani, Saurabh Dahiya, Sattva S. Neelapu, Jay Y. Spiegel, Brian T. Hill, Julio C. Chavez, Aaron P. Rapoport, Frederick L. Locke, Joseph P. McGuirk, Olalekan O. Oluwole, Charalambos Andreadis, Yi Lin, Andre Goy, Lazaros J. Lekakis, Michael D. Jain, Matthew A. Lunning, Armin Ghobadi, Gao Feng, Miriam T. Jacobs
Publikováno v:
Blood. 134:245-245
MDJ and MTJ contributed equally; FLL and AG contributed equally. Introduction Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are autologous anti-CD19 CAR T-cell therapies approved for the treatment of adults with relapsed or refrac
Autor:
Yuehui Wu, Emily Butler, Kristin Blouch, Sunil Pandit, M. Phillip DeYoung, James E. Hoffman, Aisha N. Hasan, Jonathan L. Kaufman, Aaron P. Rapoport, Amit Jain, Taiga Nishihori
Publikováno v:
Blood. 134:3134-3134
Background: Emerging clinical data demonstrate that adoptive cellular therapy has potential to be practice-changing in the management of relapsed/refractory multiple myeloma (MM). NY-ESO-1 TCR T (GSK3377794) are autologous polyclonal T cells transduc
Autor:
Miriam T. Jacobs, Abhinav Deol, Yibo Li, Javier Munoz, Andre Goy, N. Nora Bennani, Sattva S. Neelapu, Gao Feng, Matthew A. Lunning, Julie M. Vose, Armin Ghobadi, Charalambos Andreadis, Frederick L. Locke, Julio C. Chavez, Patrick M. Reagan, Alison R. Sehgal, Aaron P. Rapoport, Jay Y. Spiegel, Lazaros J. Lekakis, Brian T. Hill, Saurabh Dahiya, David B. Miklos, Joseph P. McGuirk, Olalekan O. Oluwole, Michael D. Jain, Loretta J. Nastoupil
Publikováno v:
Blood. 134:1583-1583
M.T.J. and M.D.J. contributed equally; A.G. and F.L.L. contributed equally. Introduction Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T-cell therapy that is approved for the treatment of adults with relapsed or refractory large B-